Paris, October 27, 2020 - Business France and the Galien Foundation are pleased to announce the winners of the 7th edition of the Prix Galien Medstartup. This reference ceremony, which brings together the biggest names in the pharmaceutical industry, is also an opportunity to highlight opportunities for partnerships between the United States and France in the field of medical innovation. 3 Franco-American projects were selected by a jury from the Galien Foundation on Monday, October 26th in three different categories: best collaboration in the pharmaceutical industry, best collaboration in the Healthtech sector, best collaboration dedicated to underprivileged populations or developing countries.

Since 2013, Business France and the Galien Foundation have joined forces to create the Prix Galien Medstartup with the aim of supporting the international development of the most promising French startups by connecting them to American companies. They develop new medical innovations that change the way certain diseases are treated, increase life expectancy for everyone and give hope to people with reduced mobility. The technological innovations of each winner of the Prix Galien Medstartup 2020 therefore help to meet certain global challenges in the field of healthcare and revolutionize the pharmaceutical, medical device and digital healthcare sectors.

Driven by the quality of its scientific research, its healthcare system and its public funding mechanisms, France has succeeded in establishing itself in the highly competitive medtech market. According to the French Federation of Health Industries, the biotech sector benefits from a strong dynamic of creation with 60 new biotech companies being created every year. Medtech (medical devices) and diagnostics companies represent nearly a quarter of the companies (26%).
BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY

**TreeFrog Therapeutics** in partnership with QC-Stem consortium: *Harvard’s Stem Cell Institute, Dana Farber’s Cancer Institute et la Foundation for Biomedical Research and Innovation (F.B.R.I).*

TreeFrog Therapeutics aims at providing access to safe and affordable cell therapies for millions of patients. The company has developed C-StemTM, a 3D cell culture technology which enables the mass-production and differentiation of pluripotent stem cells in bioreactors, with low costs, increased yields and preserved genomic integrity. With the nomination of the QC-Stem consortium, the Prix Galien Medstartup distinguishes an international research initiative, which brings together world-class leaders in the field of iPS-derived cell therapies from France, US and Japan, with the aim of evaluating the benefits of TreeFrog’s technology for patient safety. [https://treefrog.fr/](https://treefrog.fr/)

BEST COLLABORATION IN THE MEDTECH OR DIGITAL HEALTH SECTOR

**Wandercraft** in partnership with *Shirley Ryan Ability Lab (SRAL) and Caltech Amberlabs.*

Wandercraft’s job is to make wheelchair users walk again. They have developed the first autonomous exo. Since 2019 CE marking, hundreds of patients in Europe have walked human-like, autonomously and without crutches, with the first, Rehab version of the exo. The Wanderteam walks on the edge of robotics. They cooperate with world class university labs and medical centers in Europe and the US. [https://www.wandercraft.eu/fr/](https://www.wandercraft.eu/fr/)

BEST COLLABORATION DEDICATED TO THE DEVELOPING OR UNDERSERVED POPULATIONS WORLDWIDE

**E-Scopics** in partnership with *North Carolina State University.*

E-Scopics dematerializes Ultrasound to democratize its use to all healthcare professionals. Products are application specific Apps, downloadable on Tablets or Smartphones that connect to, and control smart digital probes. E-Scopics revolutionizes Ultrasound, leveraging advance processing techniques and AI-based imaging algorithms. This allows ultra-low power consumption systems, addressing the key issue of all ultraportable systems on the market. E-Scopics further differentiates clinically with unique”imaging biomarkers” that standardize surveillance of chronic diseases, without acquisition skills nor interpretation expertise. [https://www.e-scopics.com/](https://www.e-scopics.com/)

---

According to Arnaud Leretour, Business Director France North America, "The Prix Galien Medstartup is a great opportunity for our medtech, biotech and Health Tech start-ups to meet strategic partners (manufacturers, insurers, patient associations, investors), all gathered on the Galien Medstartup partnering platform to identify nuggets with whom they can envisage building their future in the United States through a
"The Galien Foundation, in partnership with Business France, is delighted to honor the vision and innovation of the winners of the 2020 Medstartup Award as they continue their quest for better health for patients around the world" commented Bernard Poussot, Director of Roche Holding.

ABOUT BUSINESS FRANCE:
Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France.
It promotes France’s companies, business image and nationwide attractiveness as an investment location, and also runs the VIE international internship program.
Business France has 1,500 personnel, both in France and in 55 countries throughout the world, who work with a network of partners.
Since January 2019, as part of the reform of the state support system for exports, Business France has given private partners responsibility for supporting French SMEs and mid-size companies in the following markets: Belgium, Hungary, Morocco, Norway, the Philippines and Singapore.

For further information, please visit: www.businessfrance.fr @businessfrance

ABOUT THE GALIEN FOUNDATION:
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation that improves the state of human health. Its mission is to serve as a vehicle for the open exchange of ideas that drive science and new innovations. Its vision is to catalyze the development of the next generation of innovative treatment and technologies that will improve health and save lives. Its scope is global, and their commitment to progress in medicine is both measurable and concrete. Its members express this through the establishment of productive relationships to build lasting bridges between the commercial research enterprise and local communities engaged in public policy, science, finance, academic research and the media. The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the global human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Claude Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.

For more information, visit www.galienfoundation.org.